Benchmark Maintains Buy on Humacyte, Lowers Price Target to $15
Benchmark Maintains Buy on Humacyte, Lowers Price Target to $15
Benchmark 維持對Humacyte的買入,將目標股價下調至15美元
Benchmark analyst Bruce Jackson maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $16 to $15.
基準分析師布魯斯·傑克遜維持Humacyte(納斯達克股票代碼:HUMA)的買入並將目標股價從16美元下調至15美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。